Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk Recovery 61% Clinical improvement 64% Discharge 56% c19early.com/mf Wong et al. Metformin for COVID-19 Prophylaxis Favors metformin Favors control
Wong, 1,214 patient metformin prophylaxis study: 59% lower mortality [p=0.01], 61% improved recovery [p=0.005], 64% better improvement [p=0.009], and 56% higher hospital discharge [p=0.009] https://c19p.org/wong
copied to clipboard
Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort
Wong et al., Frontiers in Endocrinology, doi:10.3389/fendo.2022.810914
7 Mar 2022    Source   PDF   Share   Tweet
Retrospective 1,214 COVID+ type 2 diabetes patients in Hong Kong, showing lower mortality and improved recovery with metformin use.
risk of death, 59.0% lower, OR 0.41, p = 0.01, treatment 786, control 428, adjusted per study, inverse propensity weighting, multivariable, RR approximated with OR.
risk of no recovery, 60.6% lower, OR 0.39, p = 0.005, treatment 786, control 428, adjusted per study, inverse propensity weighting, multivariable, RR approximated with OR.
clinical improvement, 63.5% better, OR 0.36, p = 0.009, treatment 786, control 428, adjusted per study, inverse propensity weighting, multivariable, RR approximated with OR.
risk of no hospital discharge, 55.8% lower, OR 0.44, p = 0.009, treatment 786, control 428, adjusted per study, inverse propensity weighting, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 3/7/2022, retrospective, China, Asia, peer-reviewed, 11 authors, study period 21 January, 2020 - 31 January, 2021.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit